Effect of growing degree days on autumn planted sunflower

Sunflower (Helianthus annus L.) having high degree of adaptability under wide range of climatic conditions, allow the crop to be productive in broad range of environments. Field experiments in autumn were laid out at Pir Mehr Ali Shah, Arid Agriculture University Rawalpindi, Pakistan for two years (2007 and 2008), to document the effect of growing degree days (GDD) on the performance of sunflower hybrids. Four sunflower hybrids, Alisson-RM, Parasio-24, MG-2 and S-278 were planted in randomized complete block design with four replications during autumn season. The data on growing degree days accumulation during autumn and their effect on achene, oil yield and yield components of sunflower like number of achenes per head, hundred achenes weight, biological and achene yield was recorded. All these agronomic characters as well as oil characteristics were influenced by prevailing temperature. GDD collected during autumn season was the same for both years of study. Amongst hybrids, the hybrid MG-2 showed the maximum values for all the agronomic as well as oil parameters during the autumn season. At the late planting of sunflower during autumn season, crop completes its life cycle in short duration and accumulates less heat units, thus, achene and oil yield along with yield attributes are affected accordingly.Key words: Growing degree days (GDD), yield and yield components, sunflower

Pain from a Bullet Lingers on: An Uncommon Case of Lead Toxicity

Lead toxicity from a retained bullet as a cause for abdominal pain is rarely considered. Given its unpredictable latent period and nonspecific clinical symptoms, such cases are difficult to diagnose but may be fatal if unrecognized. We present the case of a 48-year-old man who presented with complaints of abdominal pain, weight loss and constipation. His past history was significant for a gunshot wound to the left hip about 20 years before. Radiographic studies confirmed the same with the presence of numerous intra-articular bullet fragments and a calcified hemarthrosis surrounding the left femoral head. Blood lead levels were elevated following which the patient was started on chelation therapy with succimer which resulted in symptomatic improvement. The aim of this paper is to highlight the importance of considering lead toxicity from a retained bullet as a cause of abdominal pain and to review the relevant literature

Synthesis and biological properties of palladium(II) cyclometallated compounds derived from ( E )-2-((4-hydroxybenzylidene)amino)phenol

( E )-2-((4-hydroxybenzylidene)amino)phenol (iminophenol a ) reacted with Pd(OAc) 2 giving place to com- pound 1a , in which the iminophenol was bonded to palladium(II) in a κ3 - C ortho ,N,O ortho tridentate chelat- ing mode. Thus, 1a was formed by neutral mononuclear units of schematic formula Pd(C,N,O), consisting of two fused five-membered metallacycles. Self-assembly of the Pd(C,N,O) units gave place to the polynu- clear structure of 1a . Treatment of 1a with PPh 3 or PPh 2 CH 2 CH 2 PPh 2 in molar ratio Pd(II)/PPh 3 = 1/1 or Pd(II)/PPh 2 CH 2 CH 2 PPh 2 = 2/1 produced the mononuclear or dinuclear compound of schematic formula [Pd(C,N,O)(PPh 3 )] ( 2a ) or {[P d (C,N,O)] 2 ( μ2 -PPh 2 CH 2 CH 2 PPh 2 )} ( 3a ), respectively. Compounds a were char- acterized by elemental analysis, high resolution ESI-( + ) mass spectrometry, IR, and NMR. In addition, the crystal structure of the adducts 2a ·2(CH 2 Cl-CH 2 Cl) and 3a ·5(dmso) was determined by single crystal X- ray diffraction analysis. Most compounds a were noncytotoxic or poorly cytotoxic. Nonetheless, 2a was moderately cytotoxic against the MCF-7 breast and HCT-116 colon human cancer cell lines, and presented very low cytotoxicity towards normal skin human BJ cells. Compounds a showed moderate antibacterial activity against some Gram-positive ( B. subtilis and S. aureus ) and Gram-negative ( E. coli ) bacterial strains, and displayed also moderate antioxidant activity, producing 3a the best antioxidant activity. 1a changed the electrophoretic mobility of the pBluescript SK + plasmid DNA. This change followed the pattern of cisplatin , but it started at a concentration twenty times higher than with cisplatin . Moreover, compounds 1a - 3a inhibited topoisomerase IIα at concentrations of 10, 50 and 25 μM, respectively

Corrigendum to 'Cyclopalladated and cycloplatinated benzophenone imines: Antitumor, antibacterial and antioxidant activities, DNA interaction and cathepsin B inhibition' [J. Inorg. Biochem. 140 (2014) 80-88]

The magnitudes of MIC for the antibacterial activity and of the IC50 for the antioxidant activity reported in μM are really mM. Thus, in page 84: 0.18-0.34 μM is 0.18-0.34 mM; in Tables 2 and 3: μM is mM; in page 85: 0.12 and 0.14 μM is 0.12 and 0.14 mM; and in page 87: 0.12-0.14 μM is 0.12-0.14 mM. The authors apologize for any inconvenience caused

GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics

GOLPH2 is coding the 73-kDa type II Golgi membrane antigen GOLPH2/GP73. Upregulation of GOLPH2 mRNA has been recently reported in expression array analyses of prostate cancer. As GOLPH2 protein expression in prostate tissues is currently unknown, this study aimed at a comprehensive analysis of GOLPH2 protein in benign and malignant prostate lesions. Immunohistochemically detected GOLPH2 protein expression was compared with the basal cell marker p63 and the prostate cancer marker α-methylacyl-CoA racemase (AMACR) in 614 radical prostatectomy specimens. GOLPH2 exhibited a perinuclear Golgi-type staining pattern and was preferentially seen in prostatic gland epithelia. Using a semiquantitative staining intensity score, GOLPH2 expression was significantly higher in prostate cancer glands compared with normal glands (P<0.001). GOLPH2 protein was upregulated in 567 of 614 tumours (92.3%) and AMACR in 583 of 614 tumours (95%) (correlation coefficient 0.113, P=0.005). Importantly, GOLPH2 immunohistochemistry exhibited a lower level of intratumoral heterogeneity (25 vs 45%). Further, GOLPH2 upregulation was detected in 26 of 31 (84%) AMACR-negative prostate cancer cases. These data clearly suggest GOLPH2 as an additional ancillary positive marker for tissue-based diagnosis of prostate cancer

Effects of DHA- Rich n-3 Fatty Acid Supplementation on Gene Expression in Blood Mononuclear Leukocytes: The OmegAD Study

Background: Dietary fish oil, rich in n-3 fatty acids (n-3 FAs), e. g. docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), regulate inflammatory reactions by various mechanisms, e. g. gene activation. However, the effects of long-term treatment with DHA and EPA in humans, using genome wide techniques, are poorly described. Hence, our aim was to determine the effects of 6 mo of dietary supplementation with an n-3 FA preparation rich in DHA on global gene expression in peripheral blood mononuclear cells. Methods and Findings: In the present study, blood samples were obtained from a subgroup of 16 patients originating from the randomized double-blind, placebo-controlled OmegAD study, where 174 Alzheimer disease (AD) patients received daily either 1.7 g of DHA and 0.6 g EPA or placebo for 6 months. In blood samples obtained from 11 patients receiving n-3 FA and five placebo, expressions of approximately 8000 genes were assessed by gene array. Significant changes were confirmed by real-time PCR. At 6 months, the n-3 FAs group displayed significant rises of DHA and EPA plasma concentrations, as well as up-and down-regulation of nine and ten genes, respectively, was noticed. Many of these genes are involved in inflammation regulation and neurodegeneration, e. g. CD63, MAN2A1, CASP4, LOC399491, NAIP, and SORL1 and in ubiqutination processes, e. g. ANAPC5 and UBE2V1. Down-regulations of ANAPC5 and RHOB correlated to increases of plasma DHA and EPA levels. Conclusions: We suggest that 6 months of dietary n-3 FA supplementatio

Impact of opioid-free analgesia on pain severity and patient satisfaction after discharge from surgery: multispecialty, prospective cohort study in 25 countries

Background: Balancing opioid stewardship and the need for adequate analgesia following discharge after surgery is challenging. This study aimed to compare the outcomes for patients discharged with opioid versus opioid-free analgesia after common surgical procedures.Methods: This international, multicentre, prospective cohort study collected data from patients undergoing common acute and elective general surgical, urological, gynaecological, and orthopaedic procedures. The primary outcomes were patient-reported time in severe pain measured on a numerical analogue scale from 0 to 100% and patient-reported satisfaction with pain relief during the first week following discharge. Data were collected by in-hospital chart review and patient telephone interview 1 week after discharge.Results: The study recruited 4273 patients from 144 centres in 25 countries; 1311 patients (30.7%) were prescribed opioid analgesia at discharge. Patients reported being in severe pain for 10 (i.q.r. 1-30)% of the first week after discharge and rated satisfaction with analgesia as 90 (i.q.r. 80-100) of 100. After adjustment for confounders, opioid analgesia on discharge was independently associated with increased pain severity (risk ratio 1.52, 95% c.i. 1.31 to 1.76; P &lt; 0.001) and re-presentation to healthcare providers owing to side-effects of medication (OR 2.38, 95% c.i. 1.36 to 4.17; P = 0.004), but not with satisfaction with analgesia (beta coefficient 0.92, 95% c.i. -1.52 to 3.36; P = 0.468) compared with opioid-free analgesia. Although opioid prescribing varied greatly between high-income and low- and middle-income countries, patient-reported outcomes did not.Conclusion: Opioid analgesia prescription on surgical discharge is associated with a higher risk of re-presentation owing to side-effects of medication and increased patient-reported pain, but not with changes in patient-reported satisfaction. Opioid-free discharge analgesia should be adopted routinely